List of Aristada drug patents
Aristada is owned by Alkermes Inc.
Aristada contains Aripiprazole Lauroxil.
Aristada has a total of 13 drug patents out of which 0 drug patents have expired.
Aristada was authorised for market use on 05 October, 2015.
Aristada is available in suspension, extended release;intramuscular dosage forms.
Aristada can be used as treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection, treatment of schizophrenia, treatment of schizophrenia by rapid and continuous intramuscular injection.
The generics of Aristada are possible to be released after 06 April, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
| US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(9 years from now) | |
| US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(9 years from now) | |
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(10 years from now) | |
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(10 years from now) | |
| US9452131 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US10238651 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US10813928 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US9526726 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US11406632 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(16 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic